Clustering groups . | Cluster 1 . | Cluster 2 . | Cluster 3 . | Cluster 4 . |
---|---|---|---|---|
Characteristics | ||||
N, N (%) | 186 (45.50%) | 63 (15.50%) | 74 (18.00%) | 87 (21.00%) |
Males, N (%) | 107 (57.50%) | 38 (60.30%) | 36 (48.60%) | 50 (57.50%) |
Age, median (mad) | 73.0 (10.80) | 70.3 (9.60) | 75.8 (7.30) | 69.4 (8.00) |
Education years and median (mad) | 16 (3.00) | 16 (3.00) | 14 (3.00) | 14 (3.00) |
APOE4 allele carrier, N (%) | 56 (30.10%) | 17 (27.00%) | 20 (27.00%) | 28 (32.20%) |
APOE2 allele carrier, N (%) | 30 (16.10%) | 8 (12.70%) | 15 (20.30%) | 11 (12.60%) |
Health and mean (SD) | 2.10 (0.80) | 2.40 (0.80) | 2.20 (0.90) | 2.40 (1.00) |
Baseline_CMC, mean (SD) | 2.00 (1.40) | 2.20 (1.40) | 2.10 (1.50) | 2.20 (1.50) |
Gait speed, median (mad) | 113.7 (17.00) | 116.30 (17.00) | 111.45 (22.00) | 113.30 (17.50) |
WMH/TIV × 100 | 0.55* (0.04**) | 0.78 (0.07**) | 0.83* (0.10**) | 1.15 (0.10**) |
Amyloid load (PiB SUVR) | 1.42** (0.02**) | 1.41 (0.02) | 1.42 (0.03) | 1.40 (0.03) |
Clustering groups . | Cluster 1 . | Cluster 2 . | Cluster 3 . | Cluster 4 . |
---|---|---|---|---|
Characteristics | ||||
N, N (%) | 186 (45.50%) | 63 (15.50%) | 74 (18.00%) | 87 (21.00%) |
Males, N (%) | 107 (57.50%) | 38 (60.30%) | 36 (48.60%) | 50 (57.50%) |
Age, median (mad) | 73.0 (10.80) | 70.3 (9.60) | 75.8 (7.30) | 69.4 (8.00) |
Education years and median (mad) | 16 (3.00) | 16 (3.00) | 14 (3.00) | 14 (3.00) |
APOE4 allele carrier, N (%) | 56 (30.10%) | 17 (27.00%) | 20 (27.00%) | 28 (32.20%) |
APOE2 allele carrier, N (%) | 30 (16.10%) | 8 (12.70%) | 15 (20.30%) | 11 (12.60%) |
Health and mean (SD) | 2.10 (0.80) | 2.40 (0.80) | 2.20 (0.90) | 2.40 (1.00) |
Baseline_CMC, mean (SD) | 2.00 (1.40) | 2.20 (1.40) | 2.10 (1.50) | 2.20 (1.50) |
Gait speed, median (mad) | 113.7 (17.00) | 116.30 (17.00) | 111.45 (22.00) | 113.30 (17.50) |
WMH/TIV × 100 | 0.55* (0.04**) | 0.78 (0.07**) | 0.83* (0.10**) | 1.15 (0.10**) |
Amyloid load (PiB SUVR) | 1.42** (0.02**) | 1.41 (0.02) | 1.42 (0.03) | 1.40 (0.03) |
Diagnosis and cognition . | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CU, N (%) . | 168 (90.30%) . | 53 (84.10%) . | 66 (89.20%) . | 71 (81.60%) . | ||||||||||||
. | CU . | MCI . | CU . | MCI . | CU . | MCI . | CU . | MCI . | ||||||||
. | Male . | Female . | Male . | Female . | Male . | Female . | Male . | Female . | Male . | Female . | Male . | Female . | Male . | Female . | Male . | Female . |
Global | 0.75 (−0.04) | 0.54* (−0.01) | 0.31 (−0.04) | 0.08 (−0.05) | 0.25 (−0.04) | 1.01 (−0.03) | −0.07 (−0.06) | 2.18 (−0.09) | 0.58 (−0.03) | 1.1 (−0.06) | 3.96** (−0.28**) | 0.34 (−0.06) | 0.29 (−0.04) | 0.18 (−0.03) | −0.26 (−0.04) | 0.89 (−0.1) |
Memory | 0.67 (−0.03) | 0.49* (0) | −0.53 (−0.02) | 0.41 (−0.09) | −0.07** (−0.03) | 1.17 (−0.03) | −0.52 (−0.04) | 2.62 (−0.15) | 0.43 (−0.02) | 1.4 (−0.05) | 2.42** (−0.21**) | −0.57 (0.01**) | 0.09 (−0.01) | 0.23 (−0.01) | −0.65 (0) | 0.77 (−0.06) |
Executive | 0.62 (−0.05) | 0.82* (−0.03*) | 0.51 (−0.07) | −0.48 (0.01) | 0.37 (−0.05) | 0.93 (−0.05) | 0.29 (−0.07) | 0.57 (0) | 0.42 (−0.03) | 1.22 (−0.08) | 3.66 (−0.26) | −0.14 (−0.07) | 0.5 (−0.07) | 0.64 (−0.07) | 0.05 (−0.09) | 1.19** (−0.15) |
Language | 0.65 (−0.04**) | 0.3 (0) | 0.33 (−0.04**) | 0.79 (−0.12**) | −0.08** (−0.02) | 0.84 (−0.04) | −0.33** (−0.03) | 3.91 (−0.17) | 0.14 (−0.01) | 0.7 (−0.03) | 2.13 (−0.16**) | 0.05 (−0.04) | 0.19 (−0.04) | −0.08 (−0.02) | −0.84 (−0.01) | 0.44 (−0.09) |
Visuospatial | 0.62 (−0.02) | 0.34 (−0.01) | 0.3 (−0.02) | −0.73 (0.02) | 0.6 (−0.03) | 0.49 (−0.01) | 0.38 (−0.04) | 0.11 (0) | 0.72 (−0.02) | 0.41 (−0.02) | 3.56 (−0.21) | 0.36 (−0.05) | 0.29 (−0.01) | −0.1 (−0.01) | −0.19 (0.01) | 0.27 (−0.04) |
Diagnosis and cognition . | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CU, N (%) . | 168 (90.30%) . | 53 (84.10%) . | 66 (89.20%) . | 71 (81.60%) . | ||||||||||||
. | CU . | MCI . | CU . | MCI . | CU . | MCI . | CU . | MCI . | ||||||||
. | Male . | Female . | Male . | Female . | Male . | Female . | Male . | Female . | Male . | Female . | Male . | Female . | Male . | Female . | Male . | Female . |
Global | 0.75 (−0.04) | 0.54* (−0.01) | 0.31 (−0.04) | 0.08 (−0.05) | 0.25 (−0.04) | 1.01 (−0.03) | −0.07 (−0.06) | 2.18 (−0.09) | 0.58 (−0.03) | 1.1 (−0.06) | 3.96** (−0.28**) | 0.34 (−0.06) | 0.29 (−0.04) | 0.18 (−0.03) | −0.26 (−0.04) | 0.89 (−0.1) |
Memory | 0.67 (−0.03) | 0.49* (0) | −0.53 (−0.02) | 0.41 (−0.09) | −0.07** (−0.03) | 1.17 (−0.03) | −0.52 (−0.04) | 2.62 (−0.15) | 0.43 (−0.02) | 1.4 (−0.05) | 2.42** (−0.21**) | −0.57 (0.01**) | 0.09 (−0.01) | 0.23 (−0.01) | −0.65 (0) | 0.77 (−0.06) |
Executive | 0.62 (−0.05) | 0.82* (−0.03*) | 0.51 (−0.07) | −0.48 (0.01) | 0.37 (−0.05) | 0.93 (−0.05) | 0.29 (−0.07) | 0.57 (0) | 0.42 (−0.03) | 1.22 (−0.08) | 3.66 (−0.26) | −0.14 (−0.07) | 0.5 (−0.07) | 0.64 (−0.07) | 0.05 (−0.09) | 1.19** (−0.15) |
Language | 0.65 (−0.04**) | 0.3 (0) | 0.33 (−0.04**) | 0.79 (−0.12**) | −0.08** (−0.02) | 0.84 (−0.04) | −0.33** (−0.03) | 3.91 (−0.17) | 0.14 (−0.01) | 0.7 (−0.03) | 2.13 (−0.16**) | 0.05 (−0.04) | 0.19 (−0.04) | −0.08 (−0.02) | −0.84 (−0.01) | 0.44 (−0.09) |
Visuospatial | 0.62 (−0.02) | 0.34 (−0.01) | 0.3 (−0.02) | −0.73 (0.02) | 0.6 (−0.03) | 0.49 (−0.01) | 0.38 (−0.04) | 0.11 (0) | 0.72 (−0.02) | 0.41 (−0.02) | 3.56 (−0.21) | 0.36 (−0.05) | 0.29 (−0.01) | −0.1 (−0.01) | −0.19 (0.01) | 0.27 (−0.04) |
Main demographic, clinical and biomarker characteristics of the data set (Table 1). The percentages of the clusters sum to 74% of the sample, since a 26% (143 participants) have uncertain classification to any of the clusters (Spplementary Table 1). Health, how healthy the participant feels from 0 to 4 with 4 being worst; CMC, cardiovascular and metabolic conditions; CU, cognitively unimpaired; WMH/TIV × 100 (WMH in FLAIR MRI as a fraction of total intracranial volume; amyloid load, PiB SUVR-Pittsburgh compound B (PiB) PET SUVR] and mad, median absolute deviation. The four domains and their average refer to cognitive functionality, they are Z-values and higher is better cognitive score. For WMH/TIV × 100, amyloid load and the cognitive variables (Global, Memory, Executive, Language and Visuospatial), the data is presented as: estimated fitted value at the 60 years of age (estimated annual change after the age of 60 years). The values are estimated with mixed-effect models: Cluster 1 is the reference group for the models of WMH and PIB (reference group for the cognitive models are cluster 1, CU and female), single asterisk (*) signifies significant difference from 0 in intercept or slope of the reference group, whereas double asterisks (**) signify that a group is significantly different from the reference group in intercept or slope (all tests have a 0.05 confidence level and are corrected with the Satterthwaite’s method and corrected for multiple comparisons with the Holm–Šidák method).
Clustering groups . | Cluster 1 . | Cluster 2 . | Cluster 3 . | Cluster 4 . |
---|---|---|---|---|
Characteristics | ||||
N, N (%) | 186 (45.50%) | 63 (15.50%) | 74 (18.00%) | 87 (21.00%) |
Males, N (%) | 107 (57.50%) | 38 (60.30%) | 36 (48.60%) | 50 (57.50%) |
Age, median (mad) | 73.0 (10.80) | 70.3 (9.60) | 75.8 (7.30) | 69.4 (8.00) |
Education years and median (mad) | 16 (3.00) | 16 (3.00) | 14 (3.00) | 14 (3.00) |
APOE4 allele carrier, N (%) | 56 (30.10%) | 17 (27.00%) | 20 (27.00%) | 28 (32.20%) |
APOE2 allele carrier, N (%) | 30 (16.10%) | 8 (12.70%) | 15 (20.30%) | 11 (12.60%) |
Health and mean (SD) | 2.10 (0.80) | 2.40 (0.80) | 2.20 (0.90) | 2.40 (1.00) |
Baseline_CMC, mean (SD) | 2.00 (1.40) | 2.20 (1.40) | 2.10 (1.50) | 2.20 (1.50) |
Gait speed, median (mad) | 113.7 (17.00) | 116.30 (17.00) | 111.45 (22.00) | 113.30 (17.50) |
WMH/TIV × 100 | 0.55* (0.04**) | 0.78 (0.07**) | 0.83* (0.10**) | 1.15 (0.10**) |
Amyloid load (PiB SUVR) | 1.42** (0.02**) | 1.41 (0.02) | 1.42 (0.03) | 1.40 (0.03) |
Clustering groups . | Cluster 1 . | Cluster 2 . | Cluster 3 . | Cluster 4 . |
---|---|---|---|---|
Characteristics | ||||
N, N (%) | 186 (45.50%) | 63 (15.50%) | 74 (18.00%) | 87 (21.00%) |
Males, N (%) | 107 (57.50%) | 38 (60.30%) | 36 (48.60%) | 50 (57.50%) |
Age, median (mad) | 73.0 (10.80) | 70.3 (9.60) | 75.8 (7.30) | 69.4 (8.00) |
Education years and median (mad) | 16 (3.00) | 16 (3.00) | 14 (3.00) | 14 (3.00) |
APOE4 allele carrier, N (%) | 56 (30.10%) | 17 (27.00%) | 20 (27.00%) | 28 (32.20%) |
APOE2 allele carrier, N (%) | 30 (16.10%) | 8 (12.70%) | 15 (20.30%) | 11 (12.60%) |
Health and mean (SD) | 2.10 (0.80) | 2.40 (0.80) | 2.20 (0.90) | 2.40 (1.00) |
Baseline_CMC, mean (SD) | 2.00 (1.40) | 2.20 (1.40) | 2.10 (1.50) | 2.20 (1.50) |
Gait speed, median (mad) | 113.7 (17.00) | 116.30 (17.00) | 111.45 (22.00) | 113.30 (17.50) |
WMH/TIV × 100 | 0.55* (0.04**) | 0.78 (0.07**) | 0.83* (0.10**) | 1.15 (0.10**) |
Amyloid load (PiB SUVR) | 1.42** (0.02**) | 1.41 (0.02) | 1.42 (0.03) | 1.40 (0.03) |
Diagnosis and cognition . | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CU, N (%) . | 168 (90.30%) . | 53 (84.10%) . | 66 (89.20%) . | 71 (81.60%) . | ||||||||||||
. | CU . | MCI . | CU . | MCI . | CU . | MCI . | CU . | MCI . | ||||||||
. | Male . | Female . | Male . | Female . | Male . | Female . | Male . | Female . | Male . | Female . | Male . | Female . | Male . | Female . | Male . | Female . |
Global | 0.75 (−0.04) | 0.54* (−0.01) | 0.31 (−0.04) | 0.08 (−0.05) | 0.25 (−0.04) | 1.01 (−0.03) | −0.07 (−0.06) | 2.18 (−0.09) | 0.58 (−0.03) | 1.1 (−0.06) | 3.96** (−0.28**) | 0.34 (−0.06) | 0.29 (−0.04) | 0.18 (−0.03) | −0.26 (−0.04) | 0.89 (−0.1) |
Memory | 0.67 (−0.03) | 0.49* (0) | −0.53 (−0.02) | 0.41 (−0.09) | −0.07** (−0.03) | 1.17 (−0.03) | −0.52 (−0.04) | 2.62 (−0.15) | 0.43 (−0.02) | 1.4 (−0.05) | 2.42** (−0.21**) | −0.57 (0.01**) | 0.09 (−0.01) | 0.23 (−0.01) | −0.65 (0) | 0.77 (−0.06) |
Executive | 0.62 (−0.05) | 0.82* (−0.03*) | 0.51 (−0.07) | −0.48 (0.01) | 0.37 (−0.05) | 0.93 (−0.05) | 0.29 (−0.07) | 0.57 (0) | 0.42 (−0.03) | 1.22 (−0.08) | 3.66 (−0.26) | −0.14 (−0.07) | 0.5 (−0.07) | 0.64 (−0.07) | 0.05 (−0.09) | 1.19** (−0.15) |
Language | 0.65 (−0.04**) | 0.3 (0) | 0.33 (−0.04**) | 0.79 (−0.12**) | −0.08** (−0.02) | 0.84 (−0.04) | −0.33** (−0.03) | 3.91 (−0.17) | 0.14 (−0.01) | 0.7 (−0.03) | 2.13 (−0.16**) | 0.05 (−0.04) | 0.19 (−0.04) | −0.08 (−0.02) | −0.84 (−0.01) | 0.44 (−0.09) |
Visuospatial | 0.62 (−0.02) | 0.34 (−0.01) | 0.3 (−0.02) | −0.73 (0.02) | 0.6 (−0.03) | 0.49 (−0.01) | 0.38 (−0.04) | 0.11 (0) | 0.72 (−0.02) | 0.41 (−0.02) | 3.56 (−0.21) | 0.36 (−0.05) | 0.29 (−0.01) | −0.1 (−0.01) | −0.19 (0.01) | 0.27 (−0.04) |
Diagnosis and cognition . | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CU, N (%) . | 168 (90.30%) . | 53 (84.10%) . | 66 (89.20%) . | 71 (81.60%) . | ||||||||||||
. | CU . | MCI . | CU . | MCI . | CU . | MCI . | CU . | MCI . | ||||||||
. | Male . | Female . | Male . | Female . | Male . | Female . | Male . | Female . | Male . | Female . | Male . | Female . | Male . | Female . | Male . | Female . |
Global | 0.75 (−0.04) | 0.54* (−0.01) | 0.31 (−0.04) | 0.08 (−0.05) | 0.25 (−0.04) | 1.01 (−0.03) | −0.07 (−0.06) | 2.18 (−0.09) | 0.58 (−0.03) | 1.1 (−0.06) | 3.96** (−0.28**) | 0.34 (−0.06) | 0.29 (−0.04) | 0.18 (−0.03) | −0.26 (−0.04) | 0.89 (−0.1) |
Memory | 0.67 (−0.03) | 0.49* (0) | −0.53 (−0.02) | 0.41 (−0.09) | −0.07** (−0.03) | 1.17 (−0.03) | −0.52 (−0.04) | 2.62 (−0.15) | 0.43 (−0.02) | 1.4 (−0.05) | 2.42** (−0.21**) | −0.57 (0.01**) | 0.09 (−0.01) | 0.23 (−0.01) | −0.65 (0) | 0.77 (−0.06) |
Executive | 0.62 (−0.05) | 0.82* (−0.03*) | 0.51 (−0.07) | −0.48 (0.01) | 0.37 (−0.05) | 0.93 (−0.05) | 0.29 (−0.07) | 0.57 (0) | 0.42 (−0.03) | 1.22 (−0.08) | 3.66 (−0.26) | −0.14 (−0.07) | 0.5 (−0.07) | 0.64 (−0.07) | 0.05 (−0.09) | 1.19** (−0.15) |
Language | 0.65 (−0.04**) | 0.3 (0) | 0.33 (−0.04**) | 0.79 (−0.12**) | −0.08** (−0.02) | 0.84 (−0.04) | −0.33** (−0.03) | 3.91 (−0.17) | 0.14 (−0.01) | 0.7 (−0.03) | 2.13 (−0.16**) | 0.05 (−0.04) | 0.19 (−0.04) | −0.08 (−0.02) | −0.84 (−0.01) | 0.44 (−0.09) |
Visuospatial | 0.62 (−0.02) | 0.34 (−0.01) | 0.3 (−0.02) | −0.73 (0.02) | 0.6 (−0.03) | 0.49 (−0.01) | 0.38 (−0.04) | 0.11 (0) | 0.72 (−0.02) | 0.41 (−0.02) | 3.56 (−0.21) | 0.36 (−0.05) | 0.29 (−0.01) | −0.1 (−0.01) | −0.19 (0.01) | 0.27 (−0.04) |
Main demographic, clinical and biomarker characteristics of the data set (Table 1). The percentages of the clusters sum to 74% of the sample, since a 26% (143 participants) have uncertain classification to any of the clusters (Spplementary Table 1). Health, how healthy the participant feels from 0 to 4 with 4 being worst; CMC, cardiovascular and metabolic conditions; CU, cognitively unimpaired; WMH/TIV × 100 (WMH in FLAIR MRI as a fraction of total intracranial volume; amyloid load, PiB SUVR-Pittsburgh compound B (PiB) PET SUVR] and mad, median absolute deviation. The four domains and their average refer to cognitive functionality, they are Z-values and higher is better cognitive score. For WMH/TIV × 100, amyloid load and the cognitive variables (Global, Memory, Executive, Language and Visuospatial), the data is presented as: estimated fitted value at the 60 years of age (estimated annual change after the age of 60 years). The values are estimated with mixed-effect models: Cluster 1 is the reference group for the models of WMH and PIB (reference group for the cognitive models are cluster 1, CU and female), single asterisk (*) signifies significant difference from 0 in intercept or slope of the reference group, whereas double asterisks (**) signify that a group is significantly different from the reference group in intercept or slope (all tests have a 0.05 confidence level and are corrected with the Satterthwaite’s method and corrected for multiple comparisons with the Holm–Šidák method).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.